Evidence map›Paper›PMID 38778130›Full record

ArticleNature cell biology2024

Author Correction: mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.

Nicolás Herranz, Suchira Gallage, Massimiliano Mellone, Torsten Wuestefeld, Sabrina Klotz, Christopher J Hanley, Selina Raguz, Juan Carlos Acosta, Andrew J Innes, Ana Banito and 15 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature cell biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Nicolás HerranzCell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Suchira GallageCell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Massimiliano MelloneCancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton, UK.
Torsten WuestefeldDivision of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany.
Sabrina KlotzDivision of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany.
Christopher J HanleyCancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton, UK.
Selina RaguzCell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Juan Carlos AcostaCell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Andrew J InnesCell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Ana BanitoCell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Athena GeorgilisCell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Alex MontoyaProteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Katharina WolterDivision of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany.
Gopuraja DharmalingamEpigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Peter FaullProteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Thomas CarrollEpigenetics Section, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Juan Pedro Martínez-BarberaDevelopmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Institute of Child Health, London, UK.
Pedro CutillasProteomics Facility, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Florian ReisingerInstitute for Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany.
Mathias HeikenwalderInstitute for Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany.
Richard A MillerDepartment of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, Michigan, USA.
Dominic WithersMetabolic Signalling Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK.
Lars ZenderDivision of Molecular Oncology of Solid Tumors, Department of Internal Medicine I, Eberhard Karls University Tübingen, Tübingen, Germany.
Gareth J ThomasCancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton, UK.
Jesús GilCell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK. jesus.gil@csc.mrc.ac.uk.

Funding

Biotechnology and Biological Sciences Research Council BB/H020527/2
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38778130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.